Biohaven and Royalty Pharma Announce Funding Agreement Totaling up to $450 Million
Amount Raised
$450 Million
Round Type
Funding Round
New HavenBiotechnologyHealth CareTherapeuticsDescription
Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) and Royalty Pharma (Nasdaq: RPRX) announced today that Biohaven has secured up to $250 million in funding to advance the company's CGRP receptor antagonist program through the development of zavegepant (formerly known as vazegepant). The zavegepant program encompasses intranasal zavegepant as well as oral zavegepant for migraine prevention and non-migraine indications. In exchange for these funds, Royalty Pharma will obtain a 0.4% royalty on annual worldwide net sales of Nurtec® ODT and if certain zavegepant regulatory approvals are achieved, a royalty of up to 3% on annual worldwide net sales of zavegepant and success-based milestone payments. The success-based milestone payments range from 0.6x to 2.95x of the zavegepant funded amount depending on the number of regulatory approvals achieved for zavegepant (including 1.9x for the first zavegepant migraine regulatory approval) and would be paid over a ten-year period
Quick answer
Biohaven raised $450 Million in a Funding Round round, dated August 7, 2020. Biohaven is based in New Haven, Connecticut, United States.
- How much did Biohaven raise?
- Biohaven raised $450 Million in a Funding Round round on August 7, 2020.
- What does Biohaven do?
- Biohaven is a commercial-stage biopharmaceutical company with a portfolio of innovative, best-in-class therapies to improve the lives of patients with debilitating neurological and neuropsychiatric diseases, including..
- Where is Biohaven based and how big is it?
- Biohaven is based in New Haven, Connecticut, United States. Fundz records about 280 employees.
- Who are the decision-makers at Biohaven?
- Fundz holds 4 contacts at Biohaven, including the CEO. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Therapeutics and Biotechnology around the same time
Companies in the same sectors as Biohaven that raised within 45 days of this round, from Fundz verified event records.
- LAVA Therapeutics raised $83M (Series C) on September 17, 2020.
- BioNTech raised $250M on September 17, 2020.
- Vaccinex raised $2M (Seed) on September 16, 2020.
- Recursion Pharmaceuticals raised $236M on September 15, 2020.
- Escient Pharmaceuticals raised $78M (Series B) on September 14, 2020.
- Casma Therapeutics raised $50M (Series B) on September 10, 2020.
Who to call at Biohaven, and when
A new round usually means Biohaven is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Biohaven raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Biohaven, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Biohaven. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Biohaven raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Biohaven raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.